Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | BNT116 + unspecified PD-L1 antibody + unspecified VEGF antibody |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| BNT116 | BNT-116|BNT 116 | BNT116 is composed of liposomal RNAs encoding 6 tumor-associated antigens, which may potentially inhibit tumor growth (Ann Oncol (2022) 33 (suppl_7): S1095). | ||
| unspecified PD-L1 antibody | Experimental PD-L1 antibody | Immune Checkpoint Inhibitor 150 PD-L1/PD-1 antibody 137 | ||
| unspecified VEGF antibody |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|